| 2024-03-27 | +2.49 % |
|
| 2024-03-21 | +0.45 % |
|
| 2024-03-19 | +0.39 % |
|
| 2024-03-01 | +1.81 % |
|
| 2024-02-29 | -1.86 % |
|
| 2024-02-28 | -1.13 % |
- The article discusses how DENTSPLY SIRONA Inc. (NASDAQ:XRAY) stock decreased by 1.13% and provides insights into the company, its recent stock movements, and investor actions. The stock went down due to Federated Hermes Inc. reducing its holdings in DENTSPLY SIRONA and other large investors making changes to their positions in the company.
- The article discusses DENTSPLY SIRONA (NASDAQ:XRAY) stock receiving various ratings from different brokerages, with a consensus of "Moderate Buy" and an average target price of $39.50, but the stock experienced a -1.13% drop last night. The stock might have gone down due to general market conditions, news impacting the dental industry or company-specific factors.
- Summary: Leerink Partners reiterates their outperform rating on DENTSPLY SIRONA (XRAY) stock, despite various other brokerages lowering their target prices, attributing the stock's recent -1.13% decline to analyst adjustments and market sentiment.
Reason for Stock Decline: The decline in DENTSPLY SIRONA (XRAY) stock can be attributed to various brokerages, including Morgan Stanley and Stifel Nicolaus, reducing their target prices and adjusting their ratings, along with general market sentiment impacting the stock price.
|
| 2024-02-27 | -0.03 % |
|
| 2024-02-26 | -0.65 % |
|
| 2024-02-23 | +1.01 % |
|
| 2024-02-06 | +2.49 % |
|
| 2024-02-05 | -2.52 % |
|
| 2024-01-31 | -0.8 % |
|
| 2024-01-29 | +1.43 % |
|
| 2024-01-26 | -0.37 % |
|
| 2024-01-25 | +1.1 % |
|
| 2023-12-11 | -0.66 % |
- DENTSPLY SIRONA (XRAY) stock has experienced a decline due to changes in top management, a $1.1 billion impairment charge, and weakening macroeconomic factors. The company's stock has underperformed the S&P 500 in each of the past three years, and it is currently trading at 1.8x revenues, below its five-year average. The article suggests that the stock may face challenges in the uncertain macroeconomic environment, but there is potential for growth. The company's fundamentals, including revenue and earnings, have been affected by lower volume and the strengthening of the U.S. Dollar. Despite these challenges, the company is in a comfortable position to meet its obligations through the ongoing inflation shock. Ultimately, the potential for gains in XRAY stock will depend on the resolution of macroeconomic factors and market sentiment.
- The article states that DENTSPLY SIRONA(XRAY) stock is currently undervalued and presents a buying opportunity, as the stock's intrinsic value is higher than its current trading price. The low beta of the stock suggests that it may not reach its intrinsic value anytime soon, but once it does, it may be difficult to find the stock at an attractive buying range. The company is expected to have relatively muted top-line growth in the coming years. Therefore, if you are a shareholder, it may be a good time to increase your holdings, and if you are a potential investor, it may be a good time to enter the stock. However, it is important to consider other factors such as the company's management team and any risks it may be facing. There is no specific reason given in the article for why the stock went down.
|
| 2023-12-08 | -1.85 % |
|
| 2023-12-04 | +0.55 % |
|
| 2023-11-29 | -0.48 % |
|
| 2023-11-20 | +0.84 % |
|
| 2023-11-17 | +0.3 % |
|
| 2023-11-16 | +0.95 % |
|
| 2023-11-10 | +4.18 % |
|
| 2023-11-08 | -2.54 % |
|
| 2023-11-06 | -2.23 % |
|
| 2023-11-02 | -7.46 % |
|
| 2023-10-25 | -2.57 % |
|
| 2023-10-19 | -2.6 % |
|
| 2023-10-18 | +0.68 % |
|
| 2023-10-10 | +1.38 % |
|
| 2023-10-09 | -1.6 % |
|
| 2023-09-29 | +0.09 % |
|